Roctavian FDA Approval History
Last updated by Judith Stewart, BPharm on July 3, 2023.
FDA Approved: Yes (First approved June 29, 2023)
Brand name: Roctavian
Generic name: valoctocogene roxaparvovec-rvox
Dosage form: Suspension for Intravenous Infusion
Company: BioMarin Pharmaceutical Inc.
Treatment for: Hemophilia A
Roctavian (valoctocogene-roxaparvovec-rvox) is an adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A.
- Roctavian is indicated for the treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity < 1 IU/dL) without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test.
- Hemophilia A is a lifelong condition caused by a mutation in the F8 gene which responsible for producing a protein called FVIII, one of the essential blood proteins necessary for blood clotting. When severely deficient in FVIII, people with hemophilia A are at risk for painful and potentially life-threatening bleeds, which can occur spontaneously. The current standard of care for hemophilia A is preventative therapy that involves receiving infusions or injections to maintain enough clotting factor in the bloodstream to prevent bleeds.
- Roctavian is a gene therapy that is designed to replace the function of the mutated F8 gene, allowing people with severe hemophilia A to produce their own FVIII and thereby limit bleeding episodes.
- Roctavian is administered as a single-dose intravenous infusion.
- Warnings and precautions associated with Roctavian include infusion-related reactions, hepatotoxicity, thromboembolic events, and hepatocellular malignancy.
- Common adverse reactions include nausea, fatigue, headache, infusion-related reactions, vomiting, and abdominal pain.
Common laboratory abnormalities include ALT, aspartate aminotransferase (AST), lactate dehydrogenase (LDH), creatine phosphokinase (CPK), factor VIII activity levels, gamma-glutamyl transferase (GGT) and bilirubin above normal limits.
Development timeline for Roctavian
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
